Here we highlight the latest advances in HIV vaccine concepts that will expand our knowledge on how to elicit effective acquisition-prevention and/or control of simian immunodeficiency virus (SIV) replication in the nonhuman primate (NHP) model.
INTRODUCTION
Over the last 30 years, the quest for an HIV vaccine has taken us on a journey from classical empirical vaccine strategies to approaches employing sophisticated structural biology and virally vectored vaccines. Since the first clinical HIV vaccine candidate was evaluated in 1987, there have been nearly 100 clinical vaccine trials and thousands of willing volunteers. Many, if not all, of these vaccine approaches were initially tested in nonhuman primates (NHPs) prior to advancement into humans [1] . In general, simian immunodeficiency virus (SIV) and chimeric HIV/SIV (or SHIV) challenge models are used to test immunogenicity and efficacy of vaccine strategies designed to principally elicit T-cell or antibody responses, respectively. The NHP model has also been employed extensively to investigate SIV pathogenesis and questions of immunological importance, which have directly advanced the design of prototype HIV vaccines. A key point remains that the selection of challenge viruses and the challenge methodologies are pivotal in the interpretation of NHP challenge studies. The field has evolved from challenging NHP with large doses of cloned viruses, to lower dose swarm-based mucosal challenges with SIVmac251 or SIVsmE660 to more accurately reflect human HIV acquisition and infection. Furthermore, this strategy permits simultaneous analysis of SIV-specific T-cell and antibody responses after vaccination and challenge. For example, it has recently been demonstrated that the SIVsmE660 quasi-species is comprised of more neutralization sensitive viruses as compared with SIVmac251 or SIVmac239, emphasizing the significance of the challenge virus in NHP model analysis ,9-17], the evolution of the NHP challenge model has informed HIV vaccine development decisions, and continued refinement will lead to more effective products entering the clinical pipeline. However, until an absolute correlate of immunity is defined or a vaccine regimen proves effective in clinical trials and iterative studies are conducted in a relevant NHP model, (like those NHP studies highlighted below) there will be continued debate on the interpretation of data, SIV challenge virus and routes of infection in relation to human clinical vaccine trials.
Nevertheless, two significant vaccine studies have established that a HIV vaccine is possible, one performed in the NHP model and the other a large-scale clinical trial. These studies have strongly influenced the field in demonstrating efficacy either by eliciting HIV Env-specific antibodies or high frequency effector memory CD8 T cells [18, 19] .
ANTIBODIES ARE A CRUCIALCOMPONENT FOR PROTECTION FROM HIV/SIV INFECTION
The much deliberated RV144 Thai HIV vaccine trial, involved the establishment of a functional HIV-specific antibody response that blocked the ability of the virus to infect target cells at the site of exposure, thereby resulting in 'sterilizing protection'. Results from this trial demonstrated modest protection from acquisition (31.2%, P ¼ 0.04) in humans, and this effect strongly correlated with antibody responses directed toward the Env-V1/V2 loop of HIV [20, 21] . These intriguing data challenged the common conception that antibody-mediated neutralization was required to confer protection [21, 22] , an interesting conclusion for the vaccine field considering the challenges ahead for inducing broadly neutralizing antibodies (bNab). Exactly how nonneutralizing antibodies mediated effects on acquisition in the RV144 vaccine trial is the subject of discussion and reviewed in detail [21, [23] [24] [25] , but the NHP model provides an opportunity to address hypotheses regarding the mechanisms behind protection. However, modeling the modest protective vaccine effect of RV144 in NHP is problematic, requiring a large number of NHPs coupled with a suitable virus challenge regimen designed to limit the number of transmitted virus variants and an optimized repeated intra-rectal challenge [26] . Recently, Pegu et al. [8 & ] performed a pilot study that mimicked the RV144 regimen in a small number of NHP with a SIVmac251 optimized repeated challenge regimen. Three of 11 NHP immunized with ALVAC-SIV/gp120 remained uninfected after 5 SIVmac251 challenge doses. Consistent with RV144 recipients, NHPs in this pilot study had no appreciable SIV-specific CD4 or CD8 T-cell activity yet uninfected NHP demonstrated high avidity binding for the Env-V1/V2 loop with no associated antibody dependent cellular cytotoxicity activity. Consequently, an adequately powered NHP study is underway to confirm this interesting result and address the role of nonneutralizing antibody in protection from acquisition.
Nevertheless, empirically developed vaccines for common viral diseases, such as influenza, afford protection by eliciting neutralizing antibody [27] . In the past few years, highly potent and broadly neutralizing antibodies (bNabs) capable of neutralizing the majority of circulating strains of HIV-1 have been identified from HIV-infected individuals. The bNabs target four major components of the viral spike (CD4bs, V1/V2, glycan-V3 and MPER) [28] . Design of immunogens capable of eliciting bNabs is complex and challenging, especially in light of the extraordinarily high levels of somatic hypermutation observed in these antibodies [29] . It remains unclear if HIV Env-antibodies elicited during vaccination can reproduce the same degree of affinity maturation, especially in comparison with a currently licensed influenza vaccination regimen [30] . Therefore, alternative strategies for delivery of bNabs are now being considered and evaluated in NHP. Direct vectored-mediated gene transfer of bNabs into muscle tissue allows the continued secretion of the desired antibody into the bloodstream [31, 32] . Whether this strategy will deliver a long lasting optimal concentration of bNabs remains to be determined. In the interim, passive immunization of bNabs by intravenous transfer into NHP followed by subsequent mucosal SHIV challenge evaluates the serum concentration and potential efficacy of bNabs. Broadly neutralizing antibodies such as b12, 2G12, 4E10 and 2F5 can all confer protection against mucosal SHIV
KEY POINTS
Broadly neutralizing antibodies have yet to be induced by a vaccine, so current studies have focused on passive immunization as well as vectoreddelivery methods.
One group has successfully modeled the RV144 vaccine trial for the use in future vaccine studies.
The use of a rAd26/modified vaccinia Ankara virus prime-boost has shown promise in eliciting Env-specific antibody and cellular responses that limit acquisition and control heterologous SIVmac251 replication.
challenge in NHP models [33] [34] [35] [36] . A recent study by Moldt et al. [37 & ] showed that passive immunization with a highly potent bNab-PGT121 (glycan-V3 specific) completely protected all five NHP against SHIV SF162P3 challenge at an average serum concentration of 15 mg/ml, significantly lower than those previously reported for other bNabs [38] (Fig. 1) . If potent bNabs can indeed be efficacious at low concentrations, they could be delivered singly or as combination therapy [28, 39] , perhaps limiting the pathways of viral escape. Moreover, it has been shown that passive immunization with low levels of 2G12 reduces viral load in newborn macaques [40] , thereby highlighting the prospects for an additional, cost effective therapeutic strategy to combat mother-to-child transmission.
For an effective HIV-Env immunogen to mediate protection by the induction of neutralizing antibodies, it will most likely require the generation of Env-specific antibodies with exceptional levels of somatic mutation and long complimentary determining regions in the heavy chain (CDRH3 s), which are hallmarks of currently identified HIV-bNabs [29] . Although there may be no way to induce long CDR3H3 loops solely by vaccination, as they are formed by recombination events [41] , the problem of extensive affinity maturation is another hurdle unique in current vaccine designs. For example, multiple studies have demonstrated that Influenza vaccination elicits vaccineinduced antibodies with mutation rates in the V-gene that are about the same, or slightly higher as nonspecific memory B cells (5%) [30, 42] . However, CD4 binding site-specific bNab, VRC01 demonstrates a mutation rate around 30% [43] .
How are these affinity matured antibodies generated? Specialized CD4 T follicular helper cells (T FH ) are intimately associated with B-cell differentiation and survival signals in the germinal centers [44, 45] . Also, CD4 T FH cells promote somatic mutation [46] , isotype switching and generation of high affinity memory B and plasma cells [47, 48] . The possibility of eliciting antigen-specific CD4 T FH in the context of vaccination has yet to be fully explored or realized. Interestingly, most current vaccine designs tested in NHP and in clinical For future vaccine studies, it will be important to investigate whether it will be scientifically pragmatic to track T FH cells in the peripheral blood of humans and NHPs. There is currently much discussion regarding which cell markers define CD4 T FH or T FH -like cells in peripheral blood and whether those CD4 T FH -like cells are representative of germinal center CD4 T FH cell responses; however, studies have indicated that antigen-specific CD4 T FH -like cells can be detected in human blood [52, 53] . Quite recently Bentebibel et al. [54] showed that antigenspecific CD4 T FH -like cells detected in the periphery are associated with protective antibody responses after seasonal flu vaccination, suggesting this population may be useful for the evaluation of vaccine efficacy although further research is still required in this area.
CD8 T CELLS ARE A CRUCIAL COMPONENT FOR CONTROL OF HIV/SIV INFECTION
Analyses of immune correlates in the RV144 vaccine trial and the failure of the Merck STEP trial have shifted the field of HIV vaccine design from CD8 T-cell-based vaccines to vaccines that induce Envspecific antibodies and prevent HIV acquisition [21, 43, 55] . However, epitope specific CD8 T cells remain essential in the initial reduction of virus load and subsequent control following HIV and SIV infection, especially in HIV and SIV long-term CD4bs antibody b12 40 ug/ml [33] Low dose SHIV SF162P3 V3-glycan antibodies 2G12 209 ug/ml [35] High dose SHIV 89.6PD PGT121 15 ug/ml [37] High dose SHIV SF162P3 MPER antibodies 2F5 742 ug/ml [34] High dose SHIV BaL 4E10 866 ug/ml [34] High dose SHIV BaL FIGURE 1. Broadly neutralizing antibodies used in passive immunization studies. A glycosylated gp120 model of the HIV viral spike derived from [28] highlights five antibodies that have been used in passive transfer studies in NHP. The epitopes of these antibodies are indicated by color: CD4bs in red, V3 in blue and membrane-proximal region (MPER) in cyan. Average serum concentration of each mAb in protected animals before challenge is indicated as well as the dose-model and challenge strain.
controllers [56] . Few NHP studies have demonstrated significant control of virus load following SIV challenge [3 && ,57] . In general, older studies were not powered to observe differences in acquisition, despite having SIV Env included in the regimen. But an evaluation of DNA prime followed by replication incompetent recombinant Ad5 (rAd5) boost vaccine by Letvin et al. [12] was powered to address both acquisition-prevention and SIV viral control. These animals were challenged with either SIVsmE660 or SIVmac251, and a reduction in acquisition of SIVsmE660 infection correlated with robust Envspecific CD4 T-cell responses, neutralizing antibody activity and innate genetic factors. Among SIVsmE660-infected animals, peak viral loads were reduced by approximately 1 log and associated with CD8 T-cell responses. SIV-specific effector memory CD8 T cells, which display strong virus inhibitory activity, were associated with this SIVsmE660 control in vitro [58] . In vivo, effector memory CD8 T cells reside in peripheral lymphoid and mucosal tissue with the capacity to rapidly proliferate, and have been strongly associated with early virus control in NHP receiving rhCMV vector [19, 59] . In this rhCMV vector study, effector memory CD8 T cells also exerted persistent control of viral recrudescence in the absence of SIV Env-specific antibody. Extrapolation of the specific CD8 T-cell epitopes involved in control of SIVmac239 replication (for other viral vector insert design) is difficult because rhCMV generates persistent high-frequency SIV-specific effector memory CD8 T cells that target different epitopes as compared to natural SIV infection or vaccination with rAd5 encoding the same genes [60] .
Although Env-specific CD8 T-cell responses have found to be associated with higher HIV viremia in people [61] , HIV Gag-specific CD8 T-cell responses are consistently associated with effective control of viremia, especially when restricted by protective MHC class I molecules [61, 62] . In a recent study, it has been shown that CD8 T-cell cytotoxic capacity is strongly associated with disease outcome in SIV-infected NHPs and potentially in vaccines [58, 63] . Although, further defining the characteristics of effective T-cell epitopes restricted by class I molecules associated with slow or nonprogression of HIV or SIV could possibly enlighten vaccinemediated CD8 control for future vaccine design [64] .
UNIFIED ADAPTIVE IMMUNE RESPONSE APPROACH TO HIV VACCINE DESIGN
Recently, Barouch et al. [3 && ] extensively analyzed both humoral and cellular responses in NHP immunized with a rAd26/modified vaccinia Ankara virus (MVA) prime boost vector-based vaccine expressing SIVsme543 Gag, Pol and Env antigens. They observed an 80% or greater reduction in the per exposure probability of low dose intrarectal heterologous SIVmac251 challenge that correlated with Env-specific antibody. Interestingly, the central memory or effector memory CD8 T-cell responses did not correlate with this protection from acquisition. Yet, in the same study, NHP with breakthrough SIV replication after rAd26/MVA vaccination developed robust SIV-specific CD4 and CD8 T-cell responses and reduced virus replication by more than 2 logs. On the basis of these studies, an rAd26 vector expressing HIV-Env has advanced to clinical evaluation eliciting promising immunogenicity results [65, 66] . Similar findings were recently generated by Patel et al. [67] using a different vaccine regimen. In this study rhesus macaques received DNA vectors expressing SIVmac239 followed by inactivated SIVmac239 viral particles (AT-2), effectively targeting both arms of the immune system. After challenge with neutralization-sensitive SIVsmE660, two of the eight coimmunized monkeys were protected from acquisition, and this protection correlated with mucosal Envspecific antibody. Furthermore, 73% of total vaccinated NHP that became infected controlled virus replication to low levels, and this control was associated with SIV-specific CD8 T-cell responses.
Given this finding and other data now available, vector-based HIV vaccine designs will include an HIV-Env component to reduce acquisition [8 & ,68] , although additional components that potentially mediate vaccine control of HIV replication remain to be defined. As the current pipeline of vaccine candidates near the clinic, there will be a requirement for induction of Env-specific antibodies to reduce acquisition, and the activation of CD8 T cells to reduce virus replication, in a similar manner to rAd26/MVA approach in NHP challenge studies, and these compound effects will be an essential requirement for new vaccines.
CONCLUSION
HIV vaccines that are currently undergoing largescale clinical evaluation were originally designed to contain viral components best suited to elicit T-cell responses, although the majority included HIV-Env antigens. The unexpected outcome and correlates analyses of the RV144 Thai vaccine trial has prompted intense HIV-acquisition correlate evaluations and scrutiny of responses elicited by the HIVEnv components of the vaccines. It is clear that prototype HIV vaccines under evaluation in the NHP will ostensibly utilize viral vector delivery platforms delivered as homologous prime and boost or in heterologous combinations with DNA or protein constructs. Current roadblocks in vaccine development are the delivery-method or elicitation of bNabs that demonstrate high rates of somatic hypermutation, as well as the safety considerations of novel viral vectors such as human CMV. Ideally a successful HIV vaccine will develop robust antigen specific CD4 T FH T cells that will help induce and maintain a functional antibody response, while also activating only the most effective antigen-specific CD8 response. Most importantly, these new vaccines will need to be tested in a well designed and sufficiently powered NHP studies in order to best test candidates for large-scale clinical trials in humans.
